Ascenta Therapeutics is a privately-held, clinical stage biopharmaceutical company dedicated to the discovery and development of new medicines to treat cancer. Ascenta's current focus is a portfolio of novel, orally-active, small molecule drugs that restore the natural potential for cancer cells to undergo cell death (apoptosis).

Research Grants show all

NIH1

Patents show all

12Applications8Issued

Clinical Trials show all

6Phase 24Phase 1/Phase 22Phase 1

SEC Filings show all

D1

Overview

Total FundingEmployeesLast Funding DateStatus
$87,800,18051-1002010-02-06Operating

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2007-04-10$50,000,000VenturePerseusEnterprise Partners, Sofinnova Ventures, Domain Associates
2004-11-01$30,000,000Venture$45,400,000Scale Venture PartnersDomain Associates, Sofinnova Ventures, U.S. Venture Partners (USVP), Enterprise Partners
2010-02-06$1,800,180Debt_financing
2003-01-01$6,000,000Venture$8,650,000

SEC Form D Funding Events

DateOfferedSoldType
2010-02-05$15,001,500$1,800,180Debt, Option to Acquire

Key Executives

  • J. Mel Sorensen
    Executive Officer, Director
  • Louis Bock
    Director
  • Michael Powell
    Executive Officer, Director
  • Marc Lippman
    Director
  • Joel Sussman
    Executive Officer, Director
  • Norman Selby
    Director
  • Andrew E. Senyei
    Director
  • Eckard Weber
    Director